Primmune Therapeutics

aid: primmune-therapeutics
name: Primmune Therapeutics
description: Primmune Therapeutics is a clinical-stage biotechnology company headquartered in Carlsbad, California, developing
  systemic cancer immunotherapies designed to activate the immune system in a precise and controlled manner. Its lead program,
  PRTX007, is an orally administered, systemically active small-molecule agonist of toll-like receptor 7 (TLR7) engineered
  to activate plasmacytoid dendritic cells so they produce interferons, enhance antigen presentation, recruit natural killer
  cells and support cytotoxic T cell expansion, while minimizing pro-inflammatory signaling. The company was founded by researchers
  in oral small-molecule drug design and immune agonist pharmacology and has completed Phase 1 evaluation in healthy volunteers.
  Primmune operates no developer program and publishes no API product, SDK, or interface contract; its public web presence
  is a WordPress marketing and investor-relations site, whose only machine-readable surfaces are the Yoast-generated /llms.txt
  and WordPress's default /wp-json/ CMS endpoint.
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://www.primmunerx.com/wp-content/uploads/2017/12/cropped-primmune-favicon-192x192.png
url: https://raw.githubusercontent.com/api-evangelist/primmune-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Clinical Stage
- Immunotherapy
- Oncology
- Life Sciences
- Drug Discovery
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.primmunerx.com/
- type: Blog
  url: https://www.primmunerx.com/news/
- type: BlogRSS
  url: https://www.primmunerx.com/feed/
- type: PrivacyPolicy
  url: https://www.primmunerx.com/privacy-policy/
- type: LLMsTxt
  url: llms/primmune-therapeutics-llms.txt
- type: DomainSecurity
  url: security/primmune-therapeutics-domain-security.yml
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: 'Primmune is a clinical-stage drug developer whose product is the oral TLR7 agonist PRTX007, not software: its single
    public host www.primmunerx.com is a WordPress marketing and investor site where /openapi.json, /swagger.json, /api-docs,
    /graphql, /mcp and every /.well-known/ path return 404, and the only machine-readable surfaces are a Yoast-generated /llms.txt
    listing team and press-release pages and WordPress''s stock /wp-json/ CMS endpoint, which is theme infrastructure rather
    than an API the company publishes.'
  evidence:
  - url: https://www.primmunerx.com/openapi.json
    status: 404
  - url: https://www.primmunerx.com/graphql
    status: 404
  - url: https://www.primmunerx.com/.well-known/agent-card.json
    status: 404
  - url: https://www.primmunerx.com/llms.txt
    status: 200
  - url: https://www.primmunerx.com/wp-json/
    status: 200
  checked: '2026-08-26'